Prevalence of metabolic syndrome in patients with rheumatoid arthritis in Morocco: a cross-sectional study of 179 cases

Clinical Rheumatology

Volumn 33, Issue 11, 2014, Pages 1549-1555

  Abourazzak, Fatima Ezzahra ^a,b   Mansouri, Samia ^a,b   Najdi, Adil ^a   Tahiri, Latifa ^a,b   Nejjari, Chakib ^a   Harzy, Taoufik ^a,b  

^a SIDI MOHAMED BEN ABDELLAH UNIVERSITY   (Morocco)

^b HASSAN II UNIVERSITY HOSPITAL   (Morocco)

Author keywords

Metabolic syndrome; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; URIC ACID;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MOROCCO; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; URIC ACID BLOOD LEVEL; ARTHRITIS, RHEUMATOID; COMORBIDITY; MIDDLE AGED; PREVALENCE; RISK FACTOR;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; METHOTREXATE; MIDDLE AGED; MOROCCO; PREVALENCE; RISK FACTORS;

EID: 84919396284     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2570-x     Document Type: Article

References (35)

1. Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, Herrera-Diaz C, Anaya JM, Rojas-Villarraga A (2012) Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis 17 pages
2. Kitas GD, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8–14
3. Soubriera M, Mathieu S, Bruckert E (2010) Risque cardiovasculaire en rhumatologie: critères et scores. Rev Rhum Monographies 77:176–180
4. Crowson CS, Myasoedova E, Davis JM 3rd, Matteson EL, Roger VL, Therneau TM, Fitz-Gibbon P, Rodeheffer RJ, Gabriel SE (2011) Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol 38:29–35
5. Huang PL (2009) A comprehensive definition for metabolic syndrome. Dis Model Mech 2:231–237
6. da Cunha VR, Brenol CV, Brenol JC, Xavier RM (2011) Rheumatoid arthritis and metabolic syndrome. Rev Bras Reumatol 5:260–268
7. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD (2009) Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 11:R110
8. Dao HH, Do QT, Sakamoto J (2010) Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 12:R218
9. Karakoc M, Batmaz I, Sariyildiz MA, Tahtasiz M, Cevik R, Tekbas E, Yildiz I, Celepkolu T (2012) The relationship of metabolic syndrome with disease activity and the functional status in patients with rheumatoid arthritis. J Clin Med Res 4:279–285
10. Sahebari M, Goshayeshi L, Mirfeizi Z, Rezaieyazdi Z, Hatef MR, Ghayour-Mobarhan M, Akhlaghi S, Sahebkar A, Ferns GA (2011) Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis. Sci World J 11:1195–1205
11. Da Cunha VR, Brenol CV, Brenol JC, Fuchs SC, Arlindo EM, Melo IM, Machado CA, de Castro Chaves H Jr, Xavier RM (2012) Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol 41:186–191
12. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM (2008) Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 196:756–763
13. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, Ganotakis ES, Boumpas DT (2007) Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 66:28–33
14. Sharma A, Bhilave N, Sharma K, Varma V (2012) Metabolic syndrome in Indian patients with rheumatoid arthritis and its correlation with disease activity. Arthritis Res Ther 14:P66
15. Stone NJ, Bilek S, Rosenbaum S (2005) Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol 96:53E–59E
16. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group (2005) The metabolic syndrome: a new worldwide definition. Lancet 366:1059–1106
17. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R, Jellinger PS, Kendall D, Krauss RM, Neufeld ND, Petak SM, Rodbard HW, Seibel JA, Smith DA, Wilson PW (2003) ACE position statement on the insulin resistance syndrome. Endocr Pract 9:240–242
18. Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A (2008) Prevalence and factors associated with metabolic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. J Clin Rheumatol 14:74–77
19. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA, Arciello A, Valentini G, Paolisso G (2007) Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 4:130–135
20. Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM (2006) Utility of the Framingham risk score to predict the presence of coronary atherosclerosis in patients with rheumatoid arthritis. Arthritis Res Ther 8:R186
21. Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE (2008) High tenyear risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 58:2268–2274
22. Sidiropoulos PI, Karvounaris SA, Boumpas DT (2008) Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther 10:207
23. Cojocarua M, Cojocaru IM, Silosi I, Vrabie CD (2012) Metabolic syndrome in rheumatoid arthritis. J Clin Med 7:148–152
24. Emanuela E, Grazia M, Marco DR, Paola LM, Giorgio F, Marco B (2012) Inflammation as a link between obesity and metabolic syndrome. J Nutr Metab:7pages
25. Metsios GS, Stavropoulos-Kalinoglou A, Panoulas VF, Wilson M, Nevill AM, Koutedakis Y, Kitas GD (2009) Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 16:188–194
26. Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, Mediavilla JD, Navarrete N, Ramirez A et al (2009) Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 36:2204–2211
27. Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN (2008) Uric acid and the development of metabolic syndrome in women and men. Metabolism 57:845–852
28. Farkouh ME, Greenberg BP (2009) An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol 103:1227–1237
29. Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Kitas GD (2008) Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther 10:R145
30. Bijlsma JWJ, van der Goes MC, Hoes JN, Jacobs JWG, Buttgereit F, Kirwan J (2010) Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. Ann N Y Acad Sci 1193:123–126
31. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Llorca J (2010) Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy. Ann N Y Acad Sci 1193:153–159
32. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J (2006) Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83–86
33. Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M (2005) van de SR, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 32:252–255
34. Dessein PH, Tobias M, Veller MG (2006) Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 33:2425–2432
35. Giles JT, Allison M, Blumenthal RS, Post W, Gelber AC, Petri M et al (2010) Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 62:3173–3182